ABSTRACT
INTRODUCTION
Familial Mediterranean fever (FMF) is an autosomal recessively inherited disease characterized b y r e c u r r e n t e p i s o d e s o f f e v e r accompanied by serositis attacks involving the peritoneum, synovia and pleura.
1,2 FMF patients frequently experience their first attack in childhood.
Genetic mutations of the gene leading to FMF are located at the short arm of chromosome 16 . This gene encodes a protein called pyrin which prevents excessive leukocyte migration to sites of inflammation and that is exclusively expressed in granulocytes, monocytes, dendritic c e l l s a n d s e r o s a l a n d s y n o v i a l fibroblasts. [3] [4] [5] Pyrin participates in apoptosis, cell recruitment and activation of procaspase-1, also known as interleukin 1-beta (IL-1β) converting enzyme with associated processing and secretion of IL-1 and IL-8. Although the clear effect of pyrin and the molecular mechanism of MEFV mutations remain controversial, recent data supports the hypothesis that FMF is caused by loss-of-function mutations leading to increased IL-1β activation and accentuated immune activation which results in serositis including peritonitis, pleuritic and synovitis. 6 The most common complication of untreated FMF is serum amyloid A deposition in various organs, especially in the kidneys. FMF is treated with colchicine to prevent future attacks and renal amyloidosis, which may lead to the development of nephrotic syndrome and eventual chronic renal insufficiency. [1] [2] [3] Although diagnosis of FMF is primarily clinical, it is possible to confirm it by performing a MEFV gene mutation analysis. 4, 5 In the Middle East more than 85% of FMF patients have one of the following MEFV mutations: M694V, M694I, M680I, V726A, and E148Q. 2 The M694V mutation was reported to have a relatively severe phenotype, whereas V726A and E148Q have been reported with a milder disease course. [1] [2] [3] 7 FMF is more prevalent among certain ethnic groups such as the Turks, Arabs, Jews and Armenians. 8 Turkey is one of the few countries in the world having high FMF frequency with the estimated prevalence of 1:400 to 1:1000. 2, 7 Gene sequence and phenotypic characteristics of FMF patients change according to geographic regions, which include people from certain ethnic origins both in Turkey and in the World. 1, 2, [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] Unfortunately, there is a paucity of studies that have investigated the genotypic and phenotypic variations of FMF patients in southeast Turkey. 3 Therefore, we aimed to investigate the genotypic and phenotypic characteristics of children with FMF in southeastern Turkey.
MATERIALS AND METHODS
Children diagnosed as positive for MEFV gene mutations and receiving medical care from Dicle University Hospital Department of Pediatric Nephrology and Rheumatology unit between 1998 and 2013 were enrolled. FMF diagnosis was confirmed according to the Tel-Hashomer criteria. 4 A retrospective evaluation of hospital records was conducted to determine patients'age at diagnosis, sex, previous symptoms, FMF family history, parental consanguinity, MEFV genotype, duration of FMF attacks, and response to colchicine. The diagnosis of an FMF attack was done based on clinical features, including fever (>38 º C), abdominal pain and/or chest pain lasting 6-72 hours, skin rash or arthritis and laboratory findings including high erythrocyte sedimentation rate and C-reactive protein. Renal biopsy was performed in patients with nephrotic syndrome (24 hour urinary protein >40 mg/m 2 /h, hypoalbuminemia, edema and hypercholesterolemia). Renal amyloidosis was diagnosed in renal biopsy specimen based on existence of the amorphous pink amyloid deposits around the arteries, in the interstitium, or in the glomeruli with hematoxylin & eosin stain and demonstrating a Congo red stain of the pink material. Complete response to colchicine was defined as complete control of the clinical manifestations and normalization of acute phase reactants; incomplete response was defined as persistence of some clinical manifestations and/ or some elevated acute phase reactants, and no response as no improvement in attack frequency and/or severity of the disease despite colchicine treatment. 19 Exclusion criteria were having another diagnosis besides. Disease severity was scored with criteria adapted from Pras et al. 18 by Ozen et al. 19 A score ranging from 3-5 was considered mild disease, between 6-9 points was moderate disease, and greater than 9 points was designated as severe disease. 19 The study protocol was approved by the Dicle University Hospital Ethics Committee.
DNA extraction and MEFV gene analysis
T h e M E F V m u t a t i o n a n a l y s i s w a s performed via real-time PCR for the 6 most f r e q u e n t m u t a t i o n s . G e n o m i c D N A w a s extracted from 2 mL of peripheral venous blood samples collected in tubes containing EDTA (ethylenediaminetetraacetic acid). The genomic DNA was isolated using a Nucleospin Blood Kit (Qiagen-GmbH, Germany) following t h e m a n u f a c t u r e r ' s p r o t o c o l . T h e D N A concentration was determined using a NanoDrop spectrophotometer (Thermo Scientific, USA). The 6 most common mutations located in exon 2 (E148Q) and exon 10 (M694I, M694V, M680I, V726A and R761H) of the MEFV gene were determined by real-time PCR on a ABI Prism 7500 Fast (Applied Biosystems, California, USA) according to manufacturer's instructions (Dr. Zeydanli FMF type 1 mutation analysis system, Ankara, Turkey).
Statistical analysis
Statistical analyses were performed by using SPSS version 18.0 software (SPSS Inc., Chicago, IL, USA). Student's t-test was utilized to make comparisons between two independent groups of normally distributed numerical data. Comparisons of data that not normally distributed were done by the Mann-Whitney U-test or the Kruskal-Wallis test. Categorical variables were evaluated by Chi-squared test. A p-value less than 0.05 was accepted as statistically significant.
RESULTS

Demographics
The demographic and clinical characteristics of FMF subjects are outlined in Table 1 . The study enrolled 507 children of 339 unrelated families; 54% were female and the mean age was 8.6±3.7 years. There was a mean delay in diagnosis of FMF for 2.3±2.2 years (Table 1 ). There were no differences in mean age, age of symptoms onset, age at diagnosis, delay between symptoms onset and diagnosis, and disease severity scoring between female and male patients (p>0.05, data not shown).
Clinical features
A family history of FMF was documented in 60.2% of patients. Of a positive FMF family history, 49.8% only had one affected family member (n= 152), 16.6% had two affected family members (n= 84), and 13.6% had three or more family members with FMF (n= 69). Consanguineous marriages were found in 41.4% of parents (n= 201) ( Table 1) .
Most common FMF attack symptoms were abdominal pain (98.0%), fever (93.9%), and arthralgia (47.3%). The mean disease severity score was 6.1 (range 3-12) in 389 patients. The symptoms and disease severity score, attack duration and attack pattern of 452 FMF children are given at Table 2 . Moderate disease is the most frequent characteristics of patients. Severe disease, attack duration more than 72 hours and more than 4 attacks per month were the least frequent features of the FMF patients (Table 2) .
Regular colchicine use was found in 73.9% of patients, intermittent colchicine use in 22.4% of patients, and non-compliance was demonstrated in 3.6% of patients. Complete response to treatment with resolution of symptoms was achieved in 68.3%, decreased disease severity in 25.7%, and no response in 6.0% of patients. Renal amyloidosis developed in 1.4% (n= 7). Five of the patients with renal amyloidosis were homozygous for the M694V mutation and two of them were compound heterozygous with M694V/V726A and M694V/M680I mutations. Two of these patients with amyloidosis were phenotype II FMF patients.
Patient genotypes
The most frequently identified independent MEFV mutation was E148Q in 40.1% of patients followed by M694V in 25.9% and V726A in 15.8% (Table 3 (Table 6) . 3, 5, [9] [10] [11] [12] [13] [14] [15] [16] 20, 21 The most common mutation characterized in Turks is the M694V mutation with the frequency of 30-50%. The E148Q mutation occurs at a frequency ranging from 1.4-11.4% according to some previous studies. 7, 15, 16, [19] [20] [21] Although, there were disagreement regarding whether the E148Q mutation even exhibit disease, it has been reported as disease causing mutation in FMF. 20 Two recent studies from eastern and southeast Turkey reported that the E148Q mutation occurs at frequencies of 34.1% and 30.7% in these populations, respectively, which is approximate to the frequency that we identified at 40.1%. 3, 13 A study from western Turkey, reported that the M694V mutation occurs most frequently at 48.6% and is followed by the E148Q, M680I and V726A mutations. 9 A comprehensive study with adult and pediatric FMF patients from the entire country of Turkey also reported that the M694V mutation was the most frequent at 51.4%, which was followed by M680I and V726A. 5 Our study revealed a higher E148Q mutation frequency (40.1%) than our previous study (30.7%); however, the M694V frequency that we observed in present study is similar to our previous study (25.9% versus 26.0%, respectively). 3 The differences between our first and second studies may be resulted from inclusion of more patients in the latter study.
Although some previous studies 22, 23 have proposed E148Q sequence variation as a polymorphism rather than a disease causing and heterozygous (5.9±1.9 and 5.7±1.7 points, respectively) (p= 0.007).
Patients were further divided into subgroups if they had one or two E148Q, M694V, or other mutated alleles. There were no significant differences in the clinical findings between all three subgroups (p>0.05; Table 5 ). Although, response to colchicine was found to be best in E148Q subgroup and the worst in M694V subgroup, the difference between subgroups did not reach to a statistically significant level (p= 0.062) ( Table 5 ). However, significant differences were identified in mean age of symptoms onset and disease severity scores between the three subgroups (p= 0.008 and p= 0.001, respectively).The M694V subgroup had the lowest age of disease onset and the highest disease severity scores, while the E148Q subgroup demonstrated an older mean age of disease onset with the lowest severity scores (Table 5) .
DISCUSSION
Familial Mediterranean fever is a hereditary disease that is more prevalent in ethnics groups near the Mediterranean Sea.
2 Particular mutations are more frequently observed in certain ethnic groups or geographic regions. For example, the M694V mutation has been more frequently identified in Turks and North African Jews, while the V726A mutation has been found to be more prevalent in Ashkenazi Jews, Armenians, and Arabs.
1-2, 5, 7 Although, heterozygous patients tend to show relatively mild disease, heterozygous cannot be distinguished from homozygous FMF patients by disease severity. mutation, a more recent study 24 have reported 85% of their patients who were homozygous for E148Q had typical FMF attacks. During attacks, acute phase reactants have been found raised and after attacks they returned to normal limits and these patients had a good response to colchicine treatment. In other two studies 25, 26 FMF associated amyloidosis have been reported in patients who were heterozygous for E148Q and in apatient homozygous for both E148Q and V726A (E148Q V726A / E148Q V726A). Despite clinical heterogeneity, high frequency of symptoms in these previous studies are in accordance with our results.
Our results indicated that the M694V group demonstrates higher disease severity scores, while patients with the E148Q mutation have later disease onset with a milder disease course (Table 1) . Previous studies also reported more severe disease phenotypes with the M694V mutation. 3, 20 In our study, patients with homozygous mutations showed greater disease severity and earlier disease onset when compared with heterozygous, which is in accordance with previous reports. [1] [2] [3] 5 Patients that are homozygous for the M694V mutation have a highly aggressive disease course and develop renal amyloidosis. [1] [2] [3] The patients that we diagnosed with renal amyloidosis were either homozygous or compound heterozygous for the M694V mutation. In Turkey, FMF presents a heterogeneous genotype and disease course. Therefore, in our study, we found a low rate of homozygous mutations (approximately 14%) and heterogeneous clinical findings despite high rate of parental consanguinity. In some previous studies from Turkey, in spite of high consanguineous marriages rates from all over the country, low homozygosity ratios (9-12%) have been reported in FMF patients similar to our results. 12, 13 Other studies revealed that the E148Q mutation has been associated with milder FMF disease. 3, 20 Relatively mild FMF disease together with low disease severity scores were demonstrated in the majority of our patients, which may be due to the high frequency of E148Q mutations. 1, 3, 20 No significant difference in diagnosis age among different genotype subgroups of our study, may be related to ineffective use of health services in some of our patients with low socio-economic status.
A previous study about symptoms associated with FMF attacks found that 80-94% of patients demonstrated fever, 55-91% had abdominal pain, 21-84% complained of chest pain, and 27-70% had arthritis. 2 In our study, we identified relatively lower rates of chest pain (13.8%), and arthritis (15.8%). Considering the high frequency of familial FMF history in our study, early diagnosis due to alertness of family might have led to easily diagnosing FMF without some variables such as chest pain and arthritis in these patients. It is known that, FMF may manifest only with fever in younger children and therefore diagnosis is most likely delayed in small children. 27 In our study, regular and intermittent colchicine use was identified in 73.9% and 22.4% of patients, respectively. Complete response to treatment was observed in 68.3% of patients. It has been reported that response to colchicine may result in complete disappearance of attacks in 60-70% of patients, and 5% of patients are completely resistant to colchicine. 28 It is possible that in our study intermittent colchicine use might be responsible for partial or no response to treatment.
Patient with AA-type amyloidosis and positive family history of FMF but without FMF clinical features are described as phenotype II. 5 There were two patients with phenotype II in our study, both of them with homozygous mutations. This suggests that phenotype II is very rare in our FMF patients.
Highly consanguineous marriages are most common in the eastern and southeastern regions of Turkey. 12, 29 The mean rate of consanguineous marriages is 20.9% in overall Turkey, while this rate is 4.8% in western and 40.4% in eastern parts of the country. 29 Therefore, our study sample also showed high parental consanguinity (41.4%). An elevated degree of parental consanguinity may have contributed to the high rates of FMF family history, as autosomal recessive disorders tend to occur more frequently in consanguineous marriages.
Because Turkey historically located along immigration routes, it is nearly impossible to determine the exact ancestry of specific ethnic groups. Yet, inhabitants of southeastern Turkey are predominantly Kurdish and Arabic in origin. Differences in MEFV mutation gene pools between southeastern and other regions of Turkey may be due to southeastern Turkey's unique ethnic composition, and likely explains why there is a relatively high frequency of the E148Q mutation in this region. Our study and some previous reports suggest that E148Q mutation is related to FMF, 19, 30 since the frequency of E148Q is 6.5% in healthy Turkish population. 30 In conclusion, the E148Q mutation is the most frequent MEFV mutation in southeastern Turkey and is associated with milder disease phenotypes and later disease onset. This is in contrast to other regions of Turkey and the most areas of the world. This difference may be related to ethnic and geographic differences of this location. n
